Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma | Zendy

Antonio Palumbo | Zendy; Asher ChananKhan | Zendy; Katja Weisel | Zendy; Ajay K. Nooka | Zendy; Tamás Masszi | Zendy; Meral Beksaç | Zendy; Ivan Špıčka | Zendy; Vânia Hungria | Zendy; YeungChul Mun | Zendy; MaríaVictoria Mateos | Zendy; Tomer M. Mark | Zendy; Ming Qi | Zendy; Jordan M. Schecter | Zendy; Himal Amin | Zendy; Xiang Qin | Zendy; William Deraedt | Zendy; Tahamtan Ahmadi | Zendy; Andrew Spencer | Zendy; Pieter Sonneveld | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma

Author(s) -

Antonio Palumbo,

Asher ChananKhan,

Katja Weisel,

Ajay K. Nooka,

Tamás Masszi,

Meral Beksaç,

Ivan Špıčka,

Vânia Hungria,

YeungChul Mun,

MaríaVictoria Mateos,

Tomer M. Mark,

Ming Qi,

Jordan M. Schecter,

Himal Amin,

Xiang Qin,

William Deraedt,

Tahamtan Ahmadi,

Andrew Spencer,

Pieter Sonneveld

Publication year - 2016

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa1606038

Subject(s) - daratumumab , medicine , multiple myeloma , bortezomib , dexamethasone , hazard ratio , oncology , progression free survival , surgery , confidence interval , chemotherapy

Daratumumab, a human IgGκ monoclonal antibody that targets CD38, induces direct and indirect antimyeloma activity and has shown substantial efficacy as monotherapy in heavily pretreated patients with multiple myeloma, as well as in combination with bortezomib in patients with newly diagnosed multiple myeloma.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research